Have you ever thought that with this new patent protection of NeuVax, GALE will have no problem raising a lot more money to undertake its Phase 3 trials of NeuVax until the FDA grant the approval?
In fact, I think a lot of financial institutions are now chasing GALE to offer them money.
Who said it requires 89m to do the final? I think Roche will step in. I expect to see a 13D filing soon by them.Remember this news release: Galena Biopharma Announces Clinical Development Collaboration With Genentech/Roche and The Henry M. Jackson Foundation for the ...
If they have a promising product, they should have no difficulties finding partners or investors.
Roche can be knocking on their door anytime soon for a flat buyout if they have products that can potentially capture what Herceptin can't do